CTRI/2023/08/056095
Not Yet Recruiting
Phase 3
Effect of early administration of oxybutynin on outcome of posterior urethral valve in infants: a randomized controlled trial - NI
Josy Thomas0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Health Condition 1: Q642- Congenital posterior urethral valves
- Sponsor
- Josy Thomas
- Status
- Not Yet Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Infants with bladder dysfunction due to posterior urethral valve who have been adequately fulgurated.
Exclusion Criteria
- •Infants who have not undergone adequately fulgurated or who have undergone upper urinary tract diversion procedures.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 4
A randomised trial comparing the effectiveness of oxybutynin and mirabegron in reducing symptoms of frequency and urgency in patients with benign prostatic hyperplasia receiving medical treatment with tamsulosin.Health Condition 1: N401- Benign prostatic hyperplasia withlower urinary tract symptomsCTRI/2019/10/021513JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION RESEARCH96
Completed
Phase 4
Comparison of the Effectiveness of 10% Oxybutynin Topical Gel and 20% Aluminum Chloride in Patients with Primary Hyperhidrosis: a Randomized Double-Blind Controlled TrialIRCT20221110056463N2Kerman University of Medical Sciences30
Active, Not Recruiting
Phase 1
INFLUENCE OF OXYBUTYNIN - MEDRING LIGALLI ON OVERACTIVE BLADDER SYMPTOMS IN WOMEEUCTR2021-003929-30-BEigalli BV9
Completed
Phase 3
Assessing the effectiveness of oxybutynin and phenazopyridine and celecoxib in reducing complications in the treatment of bladder tumors.Malignant neoplasm of bladder.Malignant neoplasm of bladderIRCT20171225038070N1Iran University of Medical Sciences120
Not Yet Recruiting
Phase 2
sing oxytocin in individuals with body dysmorphic disorder (BDD)Body Dysmorphic DisorderMental Health - Other mental health disordersACTRN12622000429752Swinburne University of Technology46